

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)

**CAS Number:** HYDROXYGLYCOL

**Date Report Requested:** 10/16/2014

**Time Report Requested:** 05:10:18

**First Dose M/F:** NA / NA

**Lab:** NCTR

**C Number:** C97010A  
**Lock Date:** Not Entered.  
**Cage Range:** All  
**Date Range:** All  
**Reasons For Removal:** All  
**Removal Date Range:** All  
**Treatment Groups:** All  
**Study Gender:** Female  
**PWG Approval Date:** NONE

Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXYGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:18  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
<b>Disposition Summary</b>						
Animals Initially In Study	36	18	18	18	18	18
<b>Early Deaths</b>						
Moribund Sacrifice						1
Natural Death		3	1	1	1	2
Tumor>10mm						
<b>Survivors</b>						
Moribund Sacrifice						1
Natural Death	2					
Terminal Sacrifice	34	15	17	17	17	14
Tumor>10mm						
Animals Examined Microscopically	36	18	18	18	18	18
<b>ALIMENTARY SYSTEM</b>						
Intestine Large, Cecum	(0)	(0)	(0)	(1)	(1)	(0)
Intestine Large, Colon	(0)	(1)	(0)	(0)	(0)	(0)
Hyperplasia, Lymphoid						
Necrosis		1 (100%)				
Intestine Large, Rectum	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Small	(0)	(1)	(0)	(0)	(0)	(0)
Dilatation		1 (100%)				
Liver	(1)	(1)	(0)	(1)	(2)	(2)
Abscess						
Cyst						
Eosinophilic Focus				1 (100%)		
Fatty Change						
Hematopoietic Cell Proliferation					1 (50%)	
Hemorrhage						
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic						

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:18  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Inflammation, Diffuse Tension Lipidosis					1 (50%)	
Mesentery	(0)	(0)	(0)	(0)	(0)	(0)
Abscess						
Fat, Necrosis						
Inflammation						
Pancreas	(0)	(0)	(0)	(0)	(0)	(0)
Accessory Spleen						
Inflammation, Chronic						
Salivary Glands	(1)	(0)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(0)	(0)	(1)	(0)	(0)	(0)
Stomach, Glandular	(1)	(0)	(0)	(0)	(0)	(0)
Cyst	1 (100%)					
<b>CARDIOVASCULAR SYSTEM</b>						
Heart	(0)	(0)	(0)	(0)	(0)	(0)
Atrium, Thrombosis						
<b>ENDOCRINE SYSTEM</b>						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(0)
Pituitary Gland	(1)	(0)	(0)	(0)	(0)	(0)
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(1)	(0)	(0)	(0)	(0)	(0)
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(2)	(0)	(0)	(0)	(0)	(0)
Abscess	1 (50%)					
Duct, Dilatation						
Duct, Ectasia	1 (50%)					
Inflammation						
Ovary	(20)	(8)	(13)	(12)	(10)	(12)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:18  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Abscess						
Amyloid Deposition				1 (8%)		
Angiectasis						
Cyst	18 (90%)	8 (100%)	13 (100%)	11 (92%)	9 (90%)	12 (100%)
Uterus	(20)	(4)	(5)	(5)	(5)	(5)
Dilatation	1 (5%)					1 (20%)
Endometrium, Hyperplasia, Cystic	19 (95%)	3 (75%)	5 (100%)	5 (100%)	5 (100%)	4 (80%)
Vagina	(1)	(0)	(0)	(0)	(0)	(0)
Dilatation	1 (100%)					
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(36)	(18)	(18)	(18)	(18)	(18)
Myeloid Cell, Hyperplasia	2 (6%)	3 (17%)	2 (11%)	2 (11%)		
Lymph Node	(10)	(6)	(7)	(1)	(4)	(5)
Axillary, Hematopoietic Cell Proliferation					1 (25%)	
Axillary, Hyperplasia, Lymphoid	2 (20%)	3 (50%)	3 (43%)	1 (100%)	2 (50%)	2 (40%)
Axillary, Infiltration Cellular, Plasma Cell						
Axillary, Infiltration Cellular, Polymorphnuclr						
Axillary, Inflammation			1 (14%)			
Deep Cervical, Hyperplasia, Lymphoid						
Hyperplasia, Lymphoid						
Iliac, Hyperplasia, Lymphoid						
Infiltration Cellular, Plasma Cell						
Inguinal, Hematopoietic Cell Proliferation					1 (25%)	
Inguinal, Hyperplasia, Lymphoid		1 (17%)	2 (29%)			
Inguinal, Infiltration Cellular, Plasma Cell						
Inguinal, Inflammation			1 (14%)			
Lumbar, Hyperplasia, Lymphoid	1 (10%)	3 (50%)	1 (14%)			1 (20%)
Lumbar, Infiltration Cellular, Histiocyte						1 (20%)
Lumbar, Infiltration Cellular, Plasma Cell						
Mediastinal, Hemorrhage						

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Mediastinal, Hyperplasia, Lymphoid						
Mediastinal, Infiltration Cellular, Plasma Cell						
Pancreatic, Hyperplasia, Lymphoid			1 (14%)			1 (20%)
Pancreatic, Infiltration Cellular, Polymorphnuclr						
Popliteal, Hyperplasia, Lymphoid						
Prefemoral, Hyperplasia, Lymphoid						
Renal, Hematopoietic Cell Proliferation					1 (25%)	
Renal, Hyperplasia, Lymphoid	4 (40%)	1 (17%)	2 (29%)			1 (20%)
Renal, Infiltration Cellular, Plasma Cell						
Renal, Infiltration Cellular, Polymorphnuclr						
Thoracic, Hyperplasia, Lymphoid	1 (10%)					
Thoracic, Infiltration Cellular, Histiocyte						1 (20%)
Thoracic, Infiltration Cellular, Plasma Cell						
Lymph Node, Mandibular Abscess	(4)	(8)	(5)	(4)	(5)	(3)
Hematopoietic Cell Proliferation					1 (20%)	
Hyperplasia, Lymphoid	1 (25%)	6 (75%)	4 (80%)	3 (75%)	4 (80%)	2 (67%)
Infiltration Cellular, Histiocyte		1 (13%)				
Infiltration Cellular, Plasma Cell	2 (50%)	2 (25%)		1 (25%)		1 (33%)
Infiltration Cellular, Polymorphnuclr	1 (25%)					
Inflammation			1 (20%)			
Pigmentation					1 (20%)	
Lymph Node, Mesenteric Abscess	(8)	(2)	(3)	(1)	(4)	(2)
Hematopoietic Cell Proliferation					1 (25%)	
Hyperplasia, Lymphoid	7 (88%)	2 (100%)	2 (67%)	1 (100%)	4 (100%)	1 (50%)
Infiltration Cellular, Polymorphnuclr						
Spleen	(36)	(18)	(18)	(18)	(18)	(18)
Hematopoietic Cell Proliferation	7 (19%)	2 (11%)	5 (28%)	6 (33%)	9 (50%)	5 (28%)
Hyperplasia, Lymphoid	2 (6%)	1 (6%)	1 (6%)		1 (6%)	2 (11%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXYGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Hyperplasia, Lymphoid	2 (6%)	1 (6%)	1 (6%)		1 (6%)	2 (11%)
Pigmentation	1 (3%)					
Thymus	(1)	(0)	(2)	(0)	(1)	(1)
Hyperplasia, Lymphoid					1 (100%)	
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(0)	(0)	(0)	(0)	(0)	(0)
Skin, Control	(36)	(18)	(18)	(18)	(18)	(18)
Abscess						
Acanthosis						
Cyst Epithelial Inclusion	1 (3%)				2 (11%)	
Dermis, Inflammation, Granulomatous	34 (94%)	14 (78%)	15 (83%)	17 (94%)	16 (89%)	16 (89%)
Dermis, Inflammation, Pyogranulomat						
Dermis, Tail, Inflammation, Granulomatous	1 (3%)					
Dermis, Tail, Inflammation, Pyogranulomat						
Epidermis, Inflammation, Chronic Active						
Epidermis, Necrosis						
Epidermis, Tail, Inflammation, Chronic Active						
Hyperplasia, Squamous						
Infiltration Cellular, Mast Cell						
Subcut Tiss, Inflammation, Pyogranulomat	1 (3%)					
Tail, Cyst Epithelial Inclusion	9 (25%)	5 (28%)	3 (17%)	12 (67%)	5 (28%)	3 (17%)
Tail, Hemorrhage						
Skin, Site Of Application	(2)	(0)	(0)	(0)	(1)	(0)
Skin, Site of Application	(34)	(18)	(18)	(18)	(17)	(18)
Abscess						
Acanthosis		3 (17%)	5 (28%)	2 (11%)	6 (35%)	7 (39%)
Cyst Epithelial Inclusion		1 (6%)			1 (6%)	1 (6%)
Dermis, Inflammation, Chronic Active						
Dermis, Inflammation, Granulomatous	34 (100%)	16 (89%)	14 (78%)	17 (94%)	16 (94%)	16 (89%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Dermis, Inflammation, Pyogranulomat						
Epidermis, Inflammation, Chronic Active						
Hyperplasia, Squamous		1 (6%)				
Infiltration Cellular, Mast Cell			2 (11%)			1 (6%)
Subcut Tiss, Inflammation, Pyogranulomat						
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(0)	(0)	(0)	(0)	(0)
Fracture						
Skeletal Muscle	(0)	(0)	(0)	(0)	(0)	(0)
Cyst						
<b>NERVOUS SYSTEM</b>						
None						
<b>RESPIRATORY SYSTEM</b>						
Lung	(36)	(18)	(18)	(18)	(18)	(18)
Alveolar Epith, Hyperplasia	2 (6%)			1 (6%)		2 (11%)
Alveolus, Inflammation			3 (17%)		1 (6%)	
Artery, Inflammation						
Bronchiole, Inflammation						
Hemorrhage						
Infiltration Cellular, Histiocyte					1 (6%)	
Infiltration Cellular, Lymphocyte	4 (11%)	2 (11%)	2 (11%)	2 (11%)	6 (33%)	2 (11%)
Peribronchial, Inflammation						
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(3)	(1)	(1)	(1)	(2)	(0)
Cataract	1 (33%)	1 (100%)		1 (100%)	1 (50%)	
Conjunctiva, Inflammation						
Cornea, Inflammation	1 (33%)		1 (100%)		1 (50%)	
Lids, Hyperplasia, Squamous						

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAMNO SSL	CTLCREAMNO SSL	4% AHA NO SSL	10% AHA NO SSL	2% BHA NO SSL	4% BHA NO SSL
Harderian Gland	(0)	(1)	(0)	(0)	(0)	(0)
<b>URINARY SYSTEM</b>						
Kidney	(0)	(0)	(2)	(0)	(0)	(1)
Abscess						
Infiltration Cellular, Lymphocyte			1 (50%)			
Inflammation, Chronic			1 (50%)			
Inflammation, Suppurative						

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXYGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:19  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
<b>Disposition Summary</b>						
Animals Initially In Study	36	18	18	18	18	18
<b>Early Deaths</b>						
Moribund Sacrifice	1	2			2	1
Natural Death	2	2	1	1	1	2
Tumor>10mm		1	1		1	
<b>Survivors</b>						
Moribund Sacrifice						
Natural Death				1		
Terminal Sacrifice	32	12	12	16	14	15
Tumor>10mm	1	1	4			
Animals Examined Microscopically	36	18	18	18	18	17
<b>ALIMENTARY SYSTEM</b>						
Intestine Large, Cecum	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Large, Colon	(0)	(0)	(1)	(0)	(0)	(0)
Hyperplasia, Lymphoid			1 (100%)			
Necrosis						
Intestine Large, Rectum	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Small	(0)	(0)	(0)	(0)	(0)	(0)
Dilatation						
Liver	(1)	(4)	(2)	(2)	(0)	(1)
Abscess						
Cyst						
Eosinophilic Focus						
Fatty Change						
Hematopoietic Cell Proliferation						
Hemorrhage			1 (50%)			
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic		1 (25%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXYGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:19  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Inflammation, Diffuse Tension Lipidosis		1 (25%)				
Mesentery	(1)	(1)	(1)	(1)	(0)	(0)
Abscess	1 (100%)	1 (100%)				
Fat, Necrosis Inflammation				1 (100%)		
Pancreas	(0)	(0)	(0)	(1)	(0)	(1)
Accessory Spleen Inflammation, Chronic				1 (100%)		1 (100%)
Salivary Glands	(0)	(0)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(0)	(0)	(0)	(0)	(0)	(1)
Stomach, Glandular Cyst	(0)	(0)	(0)	(0)	(0)	(0)
<b>CARDIOVASCULAR SYSTEM</b>						
Heart	(0)	(1)	(0)	(0)	(0)	(0)
Atrium, Thrombosis		1 (100%)				
<b>ENDOCRINE SYSTEM</b>						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(0)
Pituitary Gland	(0)	(0)	(0)	(0)	(0)	(0)
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(0)	(0)	(0)	(0)	(0)
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(4)	(0)	(0)	(0)	(2)	(1)
Abscess						
Duct, Dilatation						
Duct, Ectasia	3 (75%)				2 (100%)	1 (100%)
Inflammation	1 (25%)					
Ovary	(19)	(9)	(12)	(9)	(8)	(9)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Abscess						1 (11%)
Amyloid Deposition						
Angiectasis		1 (11%)				
Cyst	17 (89%)	8 (89%)	12 (100%)	8 (89%)	8 (100%)	9 (100%)
Uterus	(17)	(7)	(3)	(8)	(12)	(5)
Dilatation				1 (13%)	1 (8%)	
Endometrium, Hyperplasia, Cystic	17 (100%)	7 (100%)	3 (100%)	7 (88%)	11 (92%)	5 (100%)
Vagina	(0)	(0)	(0)	(1)	(0)	(0)
Dilatation				1 (100%)		
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(35)	(18)	(18)	(17)	(18)	(17)
Myeloid Cell, Hyperplasia	3 (9%)	5 (28%)	3 (17%)	3 (18%)	2 (11%)	1 (6%)
Lymph Node	(17)	(10)	(9)	(11)	(9)	(6)
Axillary, Hematopoietic Cell Proliferation						
Axillary, Hyperplasia, Lymphoid	13 (76%)	7 (70%)	6 (67%)	8 (73%)	8 (89%)	3 (50%)
Axillary, Infiltration Cellular, Plasma Cell						
Axillary, Infiltration Cellular, Polymorphnuclr						
Axillary, Inflammation						
Deep Cervical, Hyperplasia, Lymphoid						
Hyperplasia, Lymphoid						
Iliac, Hyperplasia, Lymphoid						
Infiltration Cellular, Plasma Cell						
Inguinal, Hematopoietic Cell Proliferation						
Inguinal, Hyperplasia, Lymphoid	4 (24%)	2 (20%)	3 (33%)			2 (33%)
Inguinal, Infiltration Cellular, Plasma Cell			1 (11%)			
Inguinal, Inflammation						
Lumbar, Hyperplasia, Lymphoid	3 (18%)					2 (33%)
Lumbar, Infiltration Cellular, Histiocyte						
Lumbar, Infiltration Cellular, Plasma Cell						1 (17%)
Mediastinal, Hemorrhage		1 (10%)				

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Mediastinal, Hyperplasia, Lymphoid		1 (10%)				
Mediastinal, Infiltration Cellular, Plasma Cell						
Pancreatic, Hyperplasia, Lymphoid	1 (6%)					
Pancreatic, Infiltration Cellular, Polymorphnuclr						
Popliteal, Hyperplasia, Lymphoid						1 (17%)
Prefemoral, Hyperplasia, Lymphoid						
Renal, Hematopoietic Cell Proliferation						
Renal, Hyperplasia, Lymphoid	2 (12%)	1 (10%)		1 (9%)	2 (22%)	
Renal, Infiltration Cellular, Plasma Cell						
Renal, Infiltration Cellular, Polymorphnuclr						
Thoracic, Hyperplasia, Lymphoid	1 (6%)					
Thoracic, Infiltration Cellular, Histiocyte						
Thoracic, Infiltration Cellular, Plasma Cell						
Lymph Node, Mandibular Abscess	(8)	(5)	(3)	(5)	(5)	(7)
Hematopoietic Cell Proliferation						
Hyperplasia, Lymphoid	8 (100%)	4 (80%)	1 (33%)	3 (60%)	5 (100%)	5 (71%)
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Plasma Cell	1 (13%)	2 (40%)		1 (20%)		
Infiltration Cellular, Polymorphnuclr						
Inflammation						
Pigmentation						
Lymph Node, Mesenteric Abscess	(6)	(2)	(2)	(4)	(1)	(2)
Hematopoietic Cell Proliferation						
Hyperplasia, Lymphoid	6 (100%)	2 (100%)		2 (50%)	1 (100%)	
Infiltration Cellular, Polymorphnuclr						
Spleen	(35)	(18)	(18)	(17)	(18)	(17)
Hematopoietic Cell Proliferation	31 (89%)	16 (89%)	16 (89%)	14 (82%)	18 (100%)	14 (82%)
Hyperplasia, Lymphoid				1 (6%)		1 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Hyperplasia, Lymphoid Pigmentation				1 (6%)		1 (6%)
Thymus	(0)	(0)	(0)	(0)	(0)	(1)
Hyperplasia, Lymphoid						
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(1)	(0)	(0)	(0)	(0)	(0)
Skin, Control	(36)	(18)	(18)	(18)	(18)	(17)
Abscess						
Acanthosis	1 (3%)			1 (6%)		
Cyst Epithelial Inclusion	3 (8%)	1 (6%)			2 (11%)	
Dermis, Inflammation, Granulomatous	28 (78%)	13 (72%)	14 (78%)	15 (83%)	16 (89%)	14 (82%)
Dermis, Inflammation, Pyogranulomat						2 (12%)
Dermis, Tail, Inflammation, Granulomatous						
Dermis, Tail, Inflammation, Pyogranulomat				1 (6%)		
Epidermis, Inflammation, Chronic Active						
Epidermis, Necrosis						
Epidermis, Tail, Inflammation, Chronic Active	1 (3%)					
Hyperplasia, Squamous		1 (6%)			1 (6%)	1 (6%)
Infiltration Cellular, Mast Cell		1 (6%)				
Subcut Tiss, Inflammation, Pyogranulomat						
Tail, Cyst Epithelial Inclusion	7 (19%)	1 (6%)	4 (22%)	6 (33%)	3 (17%)	3 (18%)
Tail, Hemorrhage		1 (6%)				
Skin, Site Of Application	(1)	(0)	(0)	(0)	(0)	(0)
Skin, Site of Application	(35)	(18)	(18)	(18)	(18)	(17)
Abscess						
Acanthosis	28 (80%)	15 (83%)	16 (89%)	16 (89%)	14 (78%)	14 (82%)
Cyst Epithelial Inclusion		2 (11%)			1 (6%)	
Dermis, Inflammation, Chronic Active						
Dermis, Inflammation, Granulomatous	34 (97%)	13 (72%)	17 (94%)	16 (89%)	17 (94%)	16 (94%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Dermis, Inflammation, Pyogranulomat		1 (6%)				
Epidermis, Inflammation, Chronic Active Hyperplasia, Squamous	16 (46%)	12 (67%)	12 (67%)	13 (72%)	5 (28%)	6 (35%)
Infiltration Cellular, Mast Cell						
Subcut Tiss, Inflammation, Pyogranulomat						
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(0)	(0)	(0)	(0)	(0)
Fracture						
Skeletal Muscle	(0)	(0)	(0)	(0)	(0)	(0)
Cyst						
<b>NERVOUS SYSTEM</b>						
None						
<b>RESPIRATORY SYSTEM</b>						
Lung	(35)	(18)	(18)	(17)	(18)	(17)
Alveolar Epith, Hyperplasia	2 (6%)	2 (11%)		1 (6%)	1 (6%)	1 (6%)
Alveolus, Inflammation	1 (3%)	1 (6%)	2 (11%)	2 (12%)	2 (11%)	1 (6%)
Artery, Inflammation		1 (6%)				
Bronchiole, Inflammation					1 (6%)	
Hemorrhage			1 (6%)			
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	4 (11%)	2 (11%)	3 (17%)	2 (12%)	5 (28%)	1 (6%)
Peribronchial, Inflammation		1 (6%)				
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(3)	(1)	(0)	(2)	(1)	(4)
Cataract		1 (100%)				2 (50%)
Conjunctiva, Inflammation	1 (33%)					
Cornea, Inflammation		1 (100%)				2 (50%)
Lids, Hyperplasia, Squamous						

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXYGLYCOL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:19  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.3 MED	CTLCREAM0.3 MED	4% AHA 0.3 MED	10% AHA 0.3 MED	2% BHA 0.3 MED	4% BHA 0.3 MED
Harderian Gland	(0)	(0)	(0)	(0)	(0)	(0)
URINARY SYSTEM						
Kidney	(1)	(0)	(0)	(0)	(1)	(0)
Abscess					1 (100%)	
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic						
Inflammation, Suppurative						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXYGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:19  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
<b>Disposition Summary</b>						
Animals Initially In Study	36	18	18	18	18	18
<b>Early Deaths</b>						
Moribund Sacrifice	2	3	1	2	1	1
Natural Death	2	1	1			1
Tumor>10mm	16	13	14	15	11	8
<b>Survivors</b>						
Moribund Sacrifice						
Natural Death						
Terminal Sacrifice	9	1	1	1	6	8
Tumor>10mm	7		1			
Animals Examined Microscopically	36	18	18	18	18	18
<b>ALIMENTARY SYSTEM</b>						
Intestine Large, Cecum	(0)	(0)	(0)	(0)	(0)	(0)
Intestine Large, Colon	(0)	(0)	(0)	(0)	(0)	(0)
Hyperplasia, Lymphoid						
Necrosis						
Intestine Large, Rectum	(0)	(0)	(1)	(0)	(0)	(0)
Intestine Small	(0)	(0)	(0)	(0)	(0)	(0)
Dilatation						
Liver	(5)	(2)	(2)	(0)	(4)	(3)
Abscess						1 (33%)
Cyst					1 (25%)	
Eosinophilic Focus						
Fatty Change					1 (25%)	
Hematopoietic Cell Proliferation	1 (20%)	1 (50%)	1 (50%)			1 (33%)
Hemorrhage						
Infiltration Cellular, Lymphocyte			1 (50%)		1 (25%)	
Inflammation, Chronic		1 (50%)			1 (25%)	

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXYGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:20  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Inflammation, Diffuse Tension Lipidosis						1 (33%)
Mesentery	(0)	(0)	(0)	(0)	(0)	(0)
Abscess						
Fat, Necrosis						
Inflammation						
Pancreas	(0)	(0)	(0)	(1)	(0)	(0)
Accessory Spleen				1 (100%)		
Inflammation, Chronic						
Salivary Glands	(0)	(0)	(0)	(0)	(0)	(1)
Stomach, Forestomach	(0)	(0)	(0)	(0)	(0)	(0)
Stomach, Glandular	(0)	(0)	(0)	(0)	(0)	(0)
Cyst						
<b>CARDIOVASCULAR SYSTEM</b>						
Heart	(0)	(0)	(0)	(0)	(0)	(0)
Atrium, Thrombosis						
<b>ENDOCRINE SYSTEM</b>						
Adrenal Gland	(0)	(0)	(0)	(0)	(1)	(0)
Pituitary Gland	(0)	(0)	(0)	(0)	(0)	(0)
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(0)	(0)	(1)	(0)	(0)
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(3)	(0)	(1)	(0)	(1)	(1)
Abscess	1 (33%)					
Duct, Dilatation						
Duct, Ectasia	2 (67%)				1 (100%)	1 (100%)
Inflammation			1 (100%)			
Ovary	(22)	(8)	(8)	(8)	(11)	(11)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Abscess						
Amyloid Deposition						
Angiectasis						
Cyst	22 (100%)	8 (100%)	8 (100%)	8 (100%)	10 (91%)	11 (100%)
Uterus	(12)	(2)	(1)	(3)	(11)	(6)
Dilatation						
Endometrium, Hyperplasia, Cystic	12 (100%)	2 (100%)	1 (100%)	3 (100%)	11 (100%)	6 (100%)
Vagina	(0)	(0)	(0)	(0)	(0)	(0)
Dilatation						
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(36)	(18)	(17)	(18)	(18)	(18)
Myeloid Cell, Hyperplasia	19 (53%)	8 (44%)	9 (53%)	13 (72%)	5 (28%)	11 (61%)
Lymph Node	(30)	(16)	(15)	(17)	(16)	(15)
Axillary, Hematopoietic Cell Proliferation						
Axillary, Hyperplasia, Lymphoid	24 (80%)	10 (63%)	11 (73%)	13 (76%)	10 (63%)	9 (60%)
Axillary, Infiltration Cellular, Plasma Cell	1 (3%)	3 (19%)	3 (20%)	4 (24%)	2 (13%)	2 (13%)
Axillary, Infiltration Cellular, Polymorphnuclr				1 (6%)		
Axillary, Inflammation						
Deep Cervical, Hyperplasia, Lymphoid					1 (6%)	
Hyperplasia, Lymphoid		3 (19%)				
Iliac, Hyperplasia, Lymphoid			1 (7%)			
Infiltration Cellular, Plasma Cell				1 (6%)		
Inguinal, Hematopoietic Cell Proliferation						
Inguinal, Hyperplasia, Lymphoid	21 (70%)	6 (38%)	9 (60%)	13 (76%)	12 (75%)	6 (40%)
Inguinal, Infiltration Cellular, Plasma Cell	2 (7%)		2 (13%)	3 (18%)		
Inguinal, Inflammation						
Lumbar, Hyperplasia, Lymphoid	7 (23%)	4 (25%)	2 (13%)	2 (12%)	1 (6%)	1 (7%)
Lumbar, Infiltration Cellular, Histiocyte						
Lumbar, Infiltration Cellular, Plasma Cell			2 (13%)	2 (12%)		
Mediastinal, Hemorrhage						

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Mediastinal, Hyperplasia, Lymphoid	1 (3%)					1 (7%)
Mediastinal, Infiltration Cellular, Plasma Cell						2 (13%)
Pancreatic, Hyperplasia, Lymphoid				1 (6%)		
Pancreatic, Infiltration Cellular, Polymorphnuclr				1 (6%)		
Popliteal, Hyperplasia, Lymphoid	1 (3%)	1 (6%)				
Prefemoral, Hyperplasia, Lymphoid		1 (6%)				
Renal, Hematopoietic Cell Proliferation						
Renal, Hyperplasia, Lymphoid	1 (3%)			4 (24%)	1 (6%)	1 (7%)
Renal, Infiltration Cellular, Plasma Cell				3 (18%)		1 (7%)
Renal, Infiltration Cellular, Polymorphnuclr				1 (6%)		
Thoracic, Hyperplasia, Lymphoid	2 (7%)			1 (6%)	2 (13%)	
Thoracic, Infiltration Cellular, Histiocyte						
Thoracic, Infiltration Cellular, Plasma Cell						
Lymph Node, Mandibular Abscess	(15)	(6)	(8)	(7)	(6)	(7)
Hematopoietic Cell Proliferation		1 (17%)				
Hyperplasia, Lymphoid	13 (87%)	4 (67%)	7 (88%)	6 (86%)	5 (83%)	3 (43%)
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Plasma Cell	4 (27%)		5 (63%)	6 (86%)	1 (17%)	4 (57%)
Infiltration Cellular, Polymorphnuclr				1 (14%)		
Inflammation						
Pigmentation						
Lymph Node, Mesenteric Abscess	(2)	(2)	(0)	(3)	(2)	(2)
Hematopoietic Cell Proliferation						1 (50%)
Hyperplasia, Lymphoid	1 (50%)	2 (100%)		3 (100%)	2 (100%)	
Infiltration Cellular, Polymorphnuclr				1 (33%)		1 (50%)
Spleen	(36)	(18)	(17)	(18)	(18)	(18)
Hematopoietic Cell Proliferation	36 (100%)	17 (94%)	17 (100%)	18 (100%)	17 (94%)	18 (100%)
Hyperplasia, Lymphoid	1 (3%)					

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXYGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Hyperplasia, Lymphoid Pigmentation	1 (3%)					
Thymus	(0)	(0)	(0)	(0)	(0)	(0)
Hyperplasia, Lymphoid						
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(0)	(0)	(0)	(0)	(0)	(0)
Skin, Control	(36)	(18)	(18)	(18)	(18)	(18)
Abscess						1 (6%)
Acanthosis				1 (6%)		
Cyst Epithelial Inclusion	2 (6%)	1 (6%)			2 (11%)	
Dermis, Inflammation, Granulomatous	29 (81%)	13 (72%)	16 (89%)	17 (94%)	15 (83%)	16 (89%)
Dermis, Inflammation, Pyogranulomat		1 (6%)				1 (6%)
Dermis, Tail, Inflammation, Granulomatous						
Dermis, Tail, Inflammation, Pyogranulomat						
Epidermis, Inflammation, Chronic Active		1 (6%)				
Epidermis, Necrosis						1 (6%)
Epidermis, Tail, Inflammation, Chronic Active						
Hyperplasia, Squamous	1 (3%)	1 (6%)				
Infiltration Cellular, Mast Cell						
Subcut Tiss, Inflammation, Pyogranulomat	1 (3%)		1 (6%)			
Tail, Cyst Epithelial Inclusion	3 (8%)	1 (6%)		2 (11%)	2 (11%)	5 (28%)
Tail, Hemorrhage						
Skin, Site Of Application	(0)	(0)	(0)	(0)	(0)	(0)
Skin, Site of Application	(36)	(18)	(18)	(18)	(18)	(18)
Abscess				2 (11%)		1 (6%)
Acanthosis	33 (92%)	17 (94%)	16 (89%)	17 (94%)	15 (83%)	17 (94%)
Cyst Epithelial Inclusion	1 (3%)	1 (6%)		1 (6%)	2 (11%)	1 (6%)
Dermis, Inflammation, Chronic Active	1 (3%)					
Dermis, Inflammation, Granulomatous	31 (86%)	16 (89%)	14 (78%)	17 (94%)	15 (83%)	16 (89%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Dermis, Inflammation, Pyogranulomat		1 (6%)		2 (11%)	1 (6%)	
Epidermis, Inflammation, Chronic Active	1 (3%)	4 (22%)			3 (17%)	1 (6%)
Hyperplasia, Squamous	20 (56%)	18 (100%)	10 (56%)	14 (78%)	15 (83%)	11 (61%)
Infiltration Cellular, Mast Cell						
Subcut Tiss, Inflammation, Pyogranulomat						
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone	(0)	(0)	(0)	(0)	(0)	(0)
Fracture						
Skeletal Muscle	(0)	(0)	(0)	(0)	(0)	(0)
Cyst						
<b>NERVOUS SYSTEM</b>						
None						
<b>RESPIRATORY SYSTEM</b>						
Lung	(36)	(18)	(17)	(18)	(18)	(18)
Alveolar Epith, Hyperplasia	2 (6%)			1 (6%)	2 (11%)	
Alveolus, Inflammation	11 (31%)	6 (33%)	6 (35%)	5 (28%)	6 (33%)	2 (11%)
Artery, Inflammation						
Bronchiole, Inflammation						
Hemorrhage			1 (6%)	1 (6%)		
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	2 (6%)			3 (17%)	1 (6%)	2 (11%)
Peribronchial, Inflammation				1 (6%)		1 (6%)
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(0)	(1)	(0)	(1)	(1)	(1)
Cataract				1 (100%)		1 (100%)
Conjunctiva, Inflammation						
Cornea, Inflammation						
Lids, Hyperplasia, Squamous		1 (100%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97010-02  
 Test Type: 1-YEAR  
 Species/Strain: Mouse/SKH-1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)  
 Test Compound: alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
 CAS Number: HYDROXGLYSAL

Date Report Requested: 10/16/2014  
 Time Report Requested: 05:10:20  
 First Dose M/F: NA / NA  
 Lab: NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.6 MED	CTLCREAM0.6 MED	4% AHA 0.6 MED	10% AHA 0.6 MED	2% BHA 0.6 MED	4% BHA 0.6 MED
Harderian Gland	(1)	(0)	(0)	(0)	(0)	(0)
URINARY SYSTEM						
Kidney	(0)	(0)	(0)	(1)	(1)	(0)
Abscess						
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic						
Inflammation, Suppurative				1 (100%)		

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
<b>Disposition Summary</b>	
<b>Animals Initially In Study</b>	<b>36</b>
<b>Early Deaths</b>	
<b>Moribund Sacrifice</b>	<b>16</b>
<b>Natural Death</b>	<b>1</b>
<b>Tumor&gt;10mm</b>	<b>19</b>
<b>Survivors</b>	
<b>Moribund Sacrifice</b>	
<b>Natural Death</b>	
<b>Terminal Sacrifice</b>	
<b>Tumor&gt;10mm</b>	
<b>Animals Examined Microscopically</b>	<b>36</b>
<b>ALIMENTARY SYSTEM</b>	
Intestine Large, Cecum	(0)
Intestine Large, Colon	(0)
Hyperplasia, Lymphoid	
Necrosis	
Intestine Large, Rectum	(0)
Intestine Small	(0)
Dilatation	
Liver	(4)
Abscess	1 (25%)
Cyst	
Eosinophilic Focus	
Fatty Change	
Hematopoietic Cell Proliferation	2 (50%)
Hemorrhage	
Infiltration Cellular, Lymphocyte	1 (25%)
Inflammation, Chronic	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
Inflammation, Diffuse	
Tension Lipidosis	
Mesentery	(1)
Abscess	
Fat, Necrosis	1 (100%)
Inflammation	
Pancreas	(1)
Accessory Spleen	1 (100%)
Inflammation, Chronic	
Salivary Glands	(0)
Stomach, Forestomach	(0)
Stomach, Glandular	(0)
Cyst	
<b>CARDIOVASCULAR SYSTEM</b>	
Heart	(0)
Atrium, Thrombosis	
<b>ENDOCRINE SYSTEM</b>	
Adrenal Gland	(0)
Pituitary Gland	(1)
<b>GENERAL BODY SYSTEM</b>	
Tissue NOS	(0)
<b>GENITAL SYSTEM</b>	
Clitoral Gland	(4)
Abscess	
Duct, Dilatation	2 (50%)
Duct, Ectasia	2 (50%)
Inflammation	1 (25%)
Ovary	(12)

a - Number of animals examined microscopically at site and number of animals with lesion



**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
Abscess	
Amyloid Deposition	
Angiectasis	
Cyst	11 (92%)
Uterus	(3)
Dilatation	2 (67%)
Endometrium, Hyperplasia, Cystic	
Vagina	(0)
Dilatation	
<b>HEMATOPOIETIC SYSTEM</b>	
Bone Marrow	(35)
Myeloid Cell, Hyperplasia	27 (77%)
Lymph Node	(29)
Axillary, Hematopoietic Cell Proliferation	
Axillary, Hyperplasia, Lymphoid	19 (66%)
Axillary, Infiltration Cellular, Plasma Cell	5 (17%)
Axillary, Infiltration Cellular, Polymorphnuclr	
Axillary, Inflammation	
Deep Cervical, Hyperplasia, Lymphoid	2 (7%)
Hyperplasia, Lymphoid	
Iliac, Hyperplasia, Lymphoid	
Infiltration Cellular, Plasma Cell	
Inguinal, Hematopoietic Cell Proliferation	
Inguinal, Hyperplasia, Lymphoid	18 (62%)
Inguinal, Infiltration Cellular, Plasma Cell	6 (21%)
Inguinal, Inflammation	
Lumbar, Hyperplasia, Lymphoid	10 (34%)
Lumbar, Infiltration Cellular, Histiocyte	
Lumbar, Infiltration Cellular, Plasma Cell	1 (3%)
Mediastinal, Hemorrhage	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
Mediastinal, Hyperplasia, Lymphoid	1 (3%)
Mediastinal, Infiltration Cellular, Plasma Cell	
Pancreatic, Hyperplasia, Lymphoid	
Pancreatic, Infiltration Cellular, Polymorphnuclr	
Popliteal, Hyperplasia, Lymphoid	
Prefemoral, Hyperplasia, Lymphoid	
Renal, Hematopoietic Cell Proliferation	
Renal, Hyperplasia, Lymphoid	6 (21%)
Renal, Infiltration Cellular, Plasma Cell	1 (3%)
Renal, Infiltration Cellular, Polymorphnuclr	
Thoracic, Hyperplasia, Lymphoid	2 (7%)
Thoracic, Infiltration Cellular, Histiocyte	
Thoracic, Infiltration Cellular, Plasma Cell	1 (3%)
Lymph Node, Mandibular	(14)
Abscess	
Hematopoietic Cell Proliferation	
Hyperplasia, Lymphoid	9 (64%)
Infiltration Cellular, Histiocyte	
Infiltration Cellular, Plasma Cell	7 (50%)
Infiltration Cellular, Polymorphnuclr	
Inflammation	
Pigmentation	
Lymph Node, Mesenteric	(1)
Abscess	
Hematopoietic Cell Proliferation	
Hyperplasia, Lymphoid	1 (100%)
Infiltration Cellular, Polymorphnuclr	
Spleen	(35)
Hematopoietic Cell Proliferation	35 (100%)
Hyperplasia, Lymphoid	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
Hyperplasia, Lymphoid Pigmentation	
Thymus	(0)
Hyperplasia, Lymphoid	
<b>INTEGUMENTARY SYSTEM</b>	
Mammary Gland	(0)
Skin, Control	(36)
Abscess	
Acanthosis	
Cyst Epithelial Inclusion	2 (6%)
Dermis, Inflammation, Granulomatous	30 (83%)
Dermis, Inflammation, Pyogranulomat	
Dermis, Tail, Inflammation, Granulomatous	
Dermis, Tail, Inflammation, Pyogranulomat	
Epidermis, Inflammation, Chronic Active	
Epidermis, Necrosis	
Epidermis, Tail, Inflammation, Chronic Active	
Hyperplasia, Squamous	1 (3%)
Infiltration Cellular, Mast Cell	
Subcut Tiss, Inflammation, Pyogranulomat	1 (3%)
Tail, Cyst Epithelial Inclusion	1 (3%)
Tail, Hemorrhage	
Skin, Site Of Application	(0)
Skin, Site of Application	(36)
Abscess	2 (6%)
Acanthosis	34 (94%)
Cyst Epithelial Inclusion	2 (6%)
Dermis, Inflammation, Chronic Active	
Dermis, Inflammation, Granulomatous	36 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)  
**CAS Number:** HYDROXGLYSAL

**Date Report Requested:** 10/16/2014  
**Time Report Requested:** 05:10:20  
**First Dose M/F:** NA / NA  
**Lab:** NCTR

SKH-1/NCTR Mouse FEMALE	NO CREAM0.9 MED
Dermis, Inflammation, Pyogranulomat	
Epidermis, Inflammation, Chronic Active	1 (3%)
Hyperplasia, Squamous	12 (33%)
Infiltration Cellular, Mast Cell	
Subcut Tiss, Inflammation, Pyogranulomat	2 (6%)
<b>MUSCULOSKELETAL SYSTEM</b>	
Bone	(2)
Fracture	1 (50%)
Skeletal Muscle	(1)
Cyst	1 (100%)
<b>NERVOUS SYSTEM</b>	
None	
<b>RESPIRATORY SYSTEM</b>	
Lung	(35)
Alveolar Epith, Hyperplasia	
Alveolus, Inflammation	14 (40%)
Artery, Inflammation	
Bronchiole, Inflammation	
Hemorrhage	1 (3%)
Infiltration Cellular, Histiocyte	
Infiltration Cellular, Lymphocyte	1 (3%)
Peribronchial, Inflammation	1 (3%)
<b>SPECIAL SENSES SYSTEM</b>	
Eye	(3)
Cataract	2 (67%)
Conjunctiva, Inflammation	
Cornea, Inflammation	1 (33%)
Lids, Hyperplasia, Squamous	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 97010-02  
**Test Type:** 1-YEAR  
**Species/Strain:** Mouse/SKH-1/NCTR

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** alpha/beta Hydroxy acids (glycolic acid, salicylic acid)

**CAS Number:** HYDROXYGLYCOL

**Date Report Requested:** 10/16/2014

**Time Report Requested:** 05:10:20

**First Dose M/F:** NA / NA

**Lab:** NCTR

---

<b>SKH-1/NCTR Mouse FEMALE</b>	<b>NO CREAM0.9 MED</b>
Harderian Gland	(0)
<b>URINARY SYSTEM</b>	
Kidney	(0)
Abscess	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic	
Inflammation, Suppurative	

---

**\*\* END OF REPORT \*\***